For Q2 2026, analysts expect Cardio Diagnostics Holdings Inc to report a consensus loss per share of $2.70 on revenue projected near $3.5 million, with the stock currently trading at $1.79 compared to a bullish $60.00 average price target.
The primary focus for investors remains the company's ability to drive commercial adoption of its AI-powered cardiovascular tests and transition away from 'nominal' revenue levels.
Recent filings indicate significant challenges, with actual revenue for the quarter ending June 30 reaching only $5.4K, despite a shift toward non-reimbursement channels and new reagent shipments for an India rollout. Shareholders are also closely monitoring potential dilution from ongoing 'at-the-market' share sales used to fund operating expenses.